United States· US:72064-150_beacc534-14e1-4fd2-978f-5646edd537f0
Ayvakit
A avapritinib product containing avapritinib, registered in United States by Blueprint Medicines Corporation. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Avapritinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EX18 (avapritinib), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Avapritinib · ATC L01EX18
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of avapritinib costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Avapritinib · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- FR France$1.93
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- AVAPRITINIB
- Manufacturer
- Blueprint Medicines Corporation
- Country
- United States (US)
- ATC code
- L01EX18
- ATC class
- Avapritinib
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 13, 2026
Packs & prices · 1
- ndc1172064-150-30
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
226 interactions on record for avapritinib.
Graded by severity as the source publishes them — 142 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Avapritinib · interactions on record
226 records
- 142 severe
- 84 moderate
Most severe, free to view
- AprepitantA04AD12severe
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Avapritinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandAyvakyt 50 mg, FilmtablettenBlueprint Medicines (Switzerland) GmbH
- CzechiaAYVAKYTBlueprint Medicines (Netherlands) B.V., Amsterdam
- SpainAYVAKYT 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULABlueprint Medicines (Netherlands) B.V.
- FinlandAYVAKYTBlueprint Medicines Netherlands B.V.
- FranceAYVAKYT 50 mg, comprimé pelliculéBLUEPRINT MEDICINES (PAYS-BAS))
- BelgiumAyvakyt 50 mgBlueprint Medicines (Netherlands)
- IcelandAYVAKYTBlueprint Medicines (Netherlands) B.V.
- NetherlandsAyvakyt 50 mg filmomhulde tablettenBlueprint Medicines (Netherlands) B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ayvakyt
- Liechtenstein · Ayvakyt
- Norway · Ayvakyt
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/db2c6ac9-497d-441c-84c2-73fb2e07159a GET /v1/drugs/db2c6ac9-497d-441c-84c2-73fb2e07159a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "50",
"substance": "AVAPRITINIB",
"productndc": "72064-150",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA212608",
"marketing_category": "NDA"
}See everything about avapritinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.